Health Condition 1: G969- Disorder of central nervous system, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
AIIMS
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients admitted to the ICU who underwent CT or MRI head for evaluation of nontraumatic encephalopathy during their ICU stay in All India Institute of Medical sciences New Delhi from January 2020 to December 2024 will be screened for eligibility in the study. Nontraumatic encephalopathy is defined as any new onset disturbance or worsening of baseline cognition or behavior and neurological function. 2.If multiple imaging is being done for the same patient then the outcome of each scan will be counted separately.
Exclusion criteria
Exclusion criteria: 1.Patients who did not undergo any CT/MRI of head during their ICU stay. 2.Patients with traumatic brain injury undergoing CT/ MRI head. 3.CT/ MRI scan in post-neurosurgical patients. 4.CT/ MRI scan done before the ICU admission. 5.CT/MRI done as a follow-up of already established chronic neurological diseases. 6.CT/MRI scans performed for interventional imagery, such as a CT scan-guided procedures that the patient underwent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To elucidate the clinical predictors associated with a positive diagnosis on CT/MRI of the brain and to develop a nomogram prediction model for predicting a positive diagnostic scan. Timepoint: After approval by CTRI, the data will be collected from ICU charts will be reviewed by retrospective chart review at the following timepoints: 1.On the day of ICU admission for baseline data 2. On the day of CT/MRI brain imaging and next day for the diagnostic yield and any treatment change event 3.Till the last day of ICU stay for estimation of duration of ICU stay and mortality. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the discriminating power of the developed prediction model. Internal validation of the prediction model by splitting the entire dataset into development cohort & validation cohort at a 70:30 ratio. To evaluate the diagnostic yield of the development cohort vs the validation cohort. To evaluate the therapeutic yield of the development cohort vs the validation cohort.Timepoint: The datasetfrom retrospective chart review will collected at the following timepoints: 1.On the day of ICU admission for baseline data 2. On the day of CT/MRI brain imaging & next day for the diagnostic yield & any treatment change event 3.Till the last day of ICU stay for estimation of duration of ICU stay & mortality. | — |
Countries
India
Contacts
Public ContactMeenupriya Arasu
All India Institute of Medical Sciences, New Delhi
Outcome results
None listed